Denise Bellman
Cincinnati Children's Hospital Medical Center
7 Papers
7 Citations
Denise Bellman is an academic researcher from Cincinnati Children's Hospital Medical Center. The author has contributed to research in topics: Transplantation & Hematopoietic stem cell transplantation. The author has an hindex of 2, co-authored 7 publications.
Chat about Author
Papers
Experience with Alemtuzumab, Fludarabine, and Melphalan Reduced-Intensity Conditioning Hematopoietic Cell Transplantation in Patients with Nonmalignant Diseases Reveals Good Outcomes and That the Risk of Mixed Chimerism Depends on Underlying Disease, Stem Cell Source, and Alemtuzumab Regimen.
Rebecca A. Marsh,Marepalli B. Rao,Aharon Gefen,Denise Bellman,Parinda A. Mehta,Pooja Khandelwal,Sharat Chandra,Sonata Jodele,Kasiani C. Myers,Michael Grimley,Christopher E. Dandoy,Javier El-Bietar,Ashish R Kumar,Tom Leemhuis,Kejian Zhang,Jack J. Bleesing,Michael B. Jordan,Alexandra H. Filipovich,Stella M. Davies +18 more
TL;DR: A retrospective study of 206 patients with metabolic diseases, non-Fanconi anemia marrow failure disorders, and primary immune deficiencies who underwent 210 consecutive RIC HCT procedures at Cincinnati Children's Hospital concludes that alemtuzumab, fludarabine, and melphalan Ric HCT offers good results for many patients and that the risk of developing mixed chimerism is influenced by underlying diagnosis, graft source, and alem TZM dosing.
69
An Intermediate Alemtuzumab Schedule Reduces the Incidence of Mixed Chimerism Following Reduced-Intensity Conditioning Hematopoietic Cell Transplantation for Hemophagocytic Lymphohistiocytosis
Rebecca A. Marsh,Mi-Ok Kim,Chunyan Liu,Denise Bellman,Laura C. Hart,Michael Grimley,Ashok Kumar,Sonata Jodele,Kasiani C. Myers,Sharat Chandra,Tom Leemhuis,Parinda A. Mehta,Jack J. Bleesing,Stella M. Davies,Michael B. Jordan,Alexandra H. Filipovich +15 more
TL;DR: The findings indicate that intermediate RIC reduces the incidence of mixed chimerism, is associated with a low incidence of upfront acute GVHD, and decreases the need for additional hematopoietic cell products after HCT.
Alemtuzumab, Fludarabine, and Melphalan Reduced Intensity Conditioning Hematopoietic Cell Transplantation: Experience in over 200 Pediatric and Young Adult Patients with Primary Immune Deficiency, Metabolic, and Marrow Failure Disorders
Rebecca A. Marsh,Marepalli B. Rao,Aharon Gefen,Denise Bellman,Parinda A. Mehta,Pooja Khandelwal,Sharat Chandra,Sonata Jodele,Kasiani C. Myers,Michael Grimley,Christopher E. Dandoy,Javier El-Bietar,Ashok Kumar,Tom Leemhuis,Kejian Zhang,Jack J. Bleesing,Michael B. Jordan,Alexandra H. Filipovich,Stella M. Davies +18 more
TL;DR: Prospective collaboration among pediatric AlloHCT centers may help to provide conclusive evidence of use of S206eS239 S232 in children under the age of five.
3
Prevalence of Viral Infections in Children Undergoing First Allogenic Hematopoietic Stem Cell Transplantation: Two Year Single Center Experience
N. Ozdemir,Sonata Jodele,Kasiani C. Myers,Parinda A. Mehta,J.J. Bleesing,Michael B. Jordan,R.A. Marsch,Ashish R Kumar,Denise Bellman,Alexandra H. Filipovich,S.M. Davies,Michael Grimley +11 more
3